Ocuphire Pharma, Inc. (OCUP)

NASDAQ: OCUP · IEX Real-Time Price · USD
3.69
+0.09 (2.50%)
At close: Mar 24, 2023, 4:00 PM
3.70
+0.01 (0.27%)
After-hours: Mar 24, 2023, 6:58 PM EDT
2.5%
Market Cap 76.78M
Revenue (ttm) n/a
Net Income (ttm) -22.37M
Shares Out 20.81M
EPS (ttm) -1.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,101
Open 3.69
Previous Close 3.60
Day's Range 3.53 - 3.69
52-Week Range 1.78 - 4.43
Beta -0.07
Analysts Buy
Price Target 21.62 (+485.91%)
Earnings Date May 11, 2023

About OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also de... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Douglas Swirsky
Employees 8
Stock Exchange NASDAQ
Ticker Symbol OCUP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for OCUP stock is "Buy." The 12-month stock price forecast is $21.62, which is an increase of 485.91% from the latest price.

Price Target
$21.62
(485.91% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting

Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients

3 days ago - GlobeNewsWire

Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings

Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11 th at 20 th Angiogenesis, Exudation, and Degeneration 2023 Meeting

1 month ago - GlobeNewsWire

Ocuphire Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol® Eye Drops for Reversal of Mydriasis

If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for Reversal of Dilation If Approved Later This Year, Nyxol Could be the Only Commercially Available Eye Drop for R...

1 month ago - GlobeNewsWire

What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?

Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago - Zacks Investment Research

Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?

Ocuphire Pharma (NASDAQ: OCUP) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evaluated the use of APX3330 as a treatment for diabetic...

2 months ago - InvestorPlace

Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Oral APX3330 Achieved Statistical Significance on a Key Pre-specified Secondary Endpoint of Preventing Clinically Meaningful Progression of Diabetic Retinopathy (DR) after 24 Weeks of Treatment

2 months ago - GlobeNewsWire

Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Nyxol ® Eye Drops Potentially Offer Differentiated Mechanism of Action to Treat Age-Related Blurry Near Vision

2 months ago - GlobeNewsWire

Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis

NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult Subjects NDA Supported by Positive Phase 3 Data Demonstrating Ra...

3 months ago - GlobeNewsWire

Ocuphire Pharma, Inc. (OCUP) Just Flashed Golden Cross Signal: Do You Buy?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

3 months ago - Zacks Investment Research

Ocuphire to Present at Five Upcoming Investor/Industry Conferences

FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...

4 months ago - GlobeNewsWire

Ocuphire Pharma Enters into a Global License Agreement for Development and Commercialization of Nyxol Eye Drops for Reversal of Mydriasis, Presbyopia and Night Vision Disturbances

Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties

4 months ago - GlobeNewsWire

Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update

NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022

5 months ago - GlobeNewsWire

Ocuphire Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol® and Strategic Partnership with American Society of Ophthalmic Administrators (ASOA)

FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...

5 months ago - GlobeNewsWire

All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy

Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

Ocuphire Announces Six Poster Presentations on Nyxol and APX3330 at the American Academy of Optometry Annual Meeting

FARMINGTON HILLS, Mich., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapi...

5 months ago - GlobeNewsWire

Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference

Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT

6 months ago - GlobeNewsWire

Ocuphire Pharma Hosting Key Opinion Leader Event on Oral APX3330 for Diabetic Eye Disease

Virtual Webinar to Take Place Friday, October 14 th @ 11 AM ET

6 months ago - GlobeNewsWire

Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...

6 months ago - GlobeNewsWire

Ocuphire Announces Upcoming Presentations at European Forum 2022, Eyecelerator@AAO 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

FARMINGTON HILLS, Mich., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...

6 months ago - GlobeNewsWire

Ocuphire Pharma Receives PDFUA Fee Waiver for Nyxol New Drug Application from FDA

NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022 NDA Submission for Nyxol Eye Drops in First Indication on Track for Late 2022

6 months ago - GlobeNewsWire

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

FARMINGTON HILLS, Mich., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therap...

7 months ago - GlobeNewsWire

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Completed Final Clinical Trials and Pre-NDA FDA Meeting to Support Registration of Nyxol in Reversal of Mydriasis (RM), On Track for Late 2022 NDA Submission and Potential 2023 Approval

8 months ago - GlobeNewsWire

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

Canaccord Genuity 42 nd Annual Growth Conference on August 10, 2022

8 months ago - GlobeNewsWire

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

Issuance Extends Nyxol's U.S. Patent Protection from 2034 into 2039 for RM Indication

8 months ago - GlobeNewsWire